JNCE
$7.59
Jounce Therapeutics
($.08)
(1.04%)
JNCE
Earnings Whisper ®
N/A
2nd Quarter June 2021
Consensus:  ($0.46)
Revenue:  $16.86 Mil
Tuesday
Aug 3
6:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when JNCE reports earnings?
Beat
Meet
Miss

Where is JNCE's stock price going from here?
Up
Flat
Down
Stock chart of JNCE
Analysts
Summary of analysts' recommendations for JNCE
Score
Grade
Pivots
Resistance
$8.15
$8.00
$7.79

$7.64

Support
$7.43
$7.28
$7.07
Tweet
Growth
Description
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States.